Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2025.4477
Abstract: This study evaluates the efficacy of acoramidis in transthyretin amyloid cardiomyopathy with wild-type, transthyretin amyloid cardiomyopathy with variant, and variant subgroups (p.Val142Ile and non-p.Val142Ile). read more here.
Keywords: variant; amyloid cardiomyopathy; efficacy acoramidis; wild type ... See more keywords